Natco Pharma (NATCOPHARM) Share Price hits fresh 52-week low, now at Rs 792
- October 9, 2026
- Posted by: Kunal Singla
- Category: News
Natco Pharma Share Price moved lower in early trade and touched a fresh 52-week low of Rs 790 before trading at Rs 792, down 0.50% from the previous close of Rs 796. The company’s market capitalisation stood at Rs 15,893.53 crore, keeping Natco Pharma Share Price in focus for investors tracking Natco Pharma Stock News and Natco Pharma Share Price Today. Univest data confirms the move itself, though no company-specific trigger has been identified. The move is relevant because it places Natco Pharma Share Price at a yearly low while the business still trades with a defined valuation profile, profit metrics and sector comparison that can be checked against peers. As of 09 October 2026 at 9:22 AM IST, the latest Univest figures show a market-backed price event rather than a fully explained news-driven move.
Natco Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 792 |
| Previous Close | Rs 796 |
| Today's Move | Rs -4 (-0.5%) |
| Open | Rs 796 |
| High | Rs 800 |
| Low | Rs 790 |
| Market Capitalisation | Rs 15,893.53 crore |
Natco Pharma Ltd. (NATCOPHARM) traded at Rs 792 versus the previous close of Rs 796, a fall of 0.5%. The stock opened at Rs 796, reached a high of Rs 800, touched a low of Rs 790.
Natco Pharma Share Price opened at Rs 796, touched a high of Rs 800 and a low of Rs 790, then traded at Rs 792. The price was Rs 4 below the previous close of Rs 796 and the day change was Rs -4, or -0.50%. The fresh 52-week low at Rs 790 was also the day’s low, which means Natco Pharma Share Price has moved to a one-year low during the current session. Market capitalisation remained Rs 15,893.53 crore. In Natco Pharma Stock Analysis terms, this is a clear price event without an identified company-specific trigger, so Natco Pharma Share Price needs to be read alongside fundamentals and sector benchmarks rather than through speculation. According to latest Univest figures, the price path is narrow today, and Natco Pharma Share Price sits close to the intraday low as of 09 October 2026 at 9:22 AM IST.
For readers following Natco Pharma Share Price Live, the key numbers are simple: Rs 796 previous close, Rs 796 open, Rs 800 high and Rs 790 low. Natco Pharma Share News is therefore centered on the fresh yearly low and the small gap between the low and the last traded price. That keeps Natco Pharma Share Price on watch in Share Market Today coverage and Stocks in News discussions.
Natco Pharma Ltd. (NATCOPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,893.53 crore |
| P/E Ratio | 13.65x |
| P/B Ratio | 1.67x |
| ROE | 16.3% |
| ROCE | 17.16% |
| EPS | Rs 58.33 |
| Book Value Per Share | Rs 476.47 |
| Dividend Yield | 0.62% |
Natco Pharma Ltd. (NATCOPHARM) fundamental metrics show P/E 13.65x, P/B 1.67x, ROE 16.3%, ROCE 17.16%. Read together, these ratios describe the company’s position rather than a recommendation.
Natco Pharma Ltd. has a market capitalisation of Rs 15,893.53 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.65x, P/B at 1.67x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.3% and ROCE of 17.16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 58.33, book value per share of Rs 476.47, dividend yield of 0.62%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.34x, median ROE of 11.53%, median ROCE of 13.32%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 13.65x |
| Benchmark Median P/E | 31.34x |
| Benchmark Average P/E | 47.29x |
| Benchmark P/E Range | 3.56x to 678.22x |
| Company P/B Ratio | 1.67x |
| Benchmark Median P/B | 2.88x |
| Company ROE | 16.3% |
| Benchmark Median ROE | 11.53% |
| Company ROCE | 17.16% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 15,893.53 crore |
| Benchmark Median Market Cap | Rs 803.77 crore |
Natco Pharma Ltd. (NATCOPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.65x, which is below the benchmark median of 31.34x, a difference of -56.45%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Natco Pharma Ltd. (NATCOPHARM) has a ROE of 16.3%, which is above the benchmark median of 11.53%, a difference of +41.37%. Natco Pharma Ltd. (NATCOPHARM) has a ROCE of 17.16%, which is above the benchmark median of 13.32%, a difference of +28.83%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | ERIS | 15,911.93 | 24.76 | 3.95 | 19.23 | 14.47 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 15,517.96 | 42.17 | 2.08 | 5.97 | 8.69 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,374.69 | 22.69 | 2.69 | 12.35 | 11.74 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,423.75 | 27.24 | 4.71 | 18.41 | 24.61 |
| Marksans Pharma Ltd. | MARKSANS | 14,741.42 | 27 | 4.39 | 15.31 | 21.1 |
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.65x compared with the displayed peer median of 27x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 16.3% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 17.16% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of Rs 15,893.53 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Natco Pharma
- Natco Pharma Share Price touched a fresh 52-week low of Rs 790 and is trading at Rs 792.
- Natco Pharma Share Price is supported by a P/E of 13.65, which is below the industry benchmark median.
- Natco Pharma Share Price shows ROE of 16.3% and ROCE of 17.16%, both above the benchmark median.
- Natco Pharma Share News now sits alongside Jun 2026 revenue of Rs 735.2 crore.
- Natco Pharma Share Price is being compared with peers that trade on higher P/E and P/B levels.
About Natco Pharma
Natco Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. Natco Pharma Share Price reflects a company that is evaluated through profitability ratios, balance-sheet values and revenue generation rather than only through intraday movement. The latest Univest figures show Jun 2026 revenue of Rs 735.2 crore, along with EPS of Rs 58.33 and book value of Rs 476.47, which help frame the business profile behind Natco Pharma Share Price.
Natco Pharma Stock News is therefore linked to a business with measurable earnings, a defined dividend yield of 0.62% and returns on equity and capital employed that are both positive. Natco Pharma Share Price is also read against a peer set that includes other listed pharmaceutical names in the same industry, making company context important for investors following Natco Pharma Latest News and Natco Pharma Share Price Update.
Track Natco Pharma Share Price on Univest
Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Natco Pharma Share Price on Univest for live share price movement, valuation ratios, 52-week levels, market capitalisation, peer context and market insights. Univest keeps Natco Pharma Share Price, Natco Pharma Stock Analysis and Natco Pharma Fundamental Analysis in one place for readers monitoring Natco Pharma Share Price Today and Natco Pharma Company News.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Natco Pharma Share Price hit a fresh 52-week low?
Ans. Natco Pharma Share Price touched Rs 790, a fresh 52-week low, and traded at Rs 792. Univest data confirms the move itself, though no company-specific trigger has been identified.
What is Natco Pharma Share Price today?
Ans. Natco Pharma Share Price was trading at Rs 792, down Rs 4 or 0.50% from the previous close of Rs 796. It opened at Rs 796 and moved between Rs 790 and Rs 800 during the session.
What is the fresh 52-week low for Natco Pharma?
Ans. The fresh 52-week low for Natco Pharma Share Price is Rs 790. That level was also the day’s low, so the stock is currently trading very near its intraday floor.
How large is Natco Pharma in market value terms?
Ans. Natco Pharma Share Price corresponds to a market capitalisation of Rs 15,893.53 crore. That figure places the company well above the benchmark median for its industry and close to several listed pharmaceutical peers.
What does Natco Pharma Fundamental Analysis show?
Ans. Natco Pharma Share Price is backed by a P/E of 13.65, P/B of 1.67, ROE of 16.3%, ROCE of 17.16%, EPS of Rs 58.33 and book value of Rs 476.47, which gives clear valuation and profitability context.
How does Natco Pharma compare with its industry benchmark?
Ans. Natco Pharma Share Price trades below the industry benchmark median on P/E and P/B, while its ROE and ROCE are above the median. That combination makes the valuation and return profile worth monitoring.
What is Natco Pharma Share Price valuation relative to peers?
Ans. Natco Pharma Share Price is lower-valued than several peers on P/E and P/B, including Eris Lifesciences, Jubilant Pharmova and Alembic Pharmaceuticals. Its market cap is also close to a few peers in the same industry.
What revenue figure should investors note for Natco Pharma?
Ans. Natco Pharma Financial Results for Jun 2026 show revenue of Rs 735.2 crore. That number helps frame Natco Pharma Share Price alongside earnings, book value and profitability ratios without relying on price alone.
Where can investors track Natco Pharma Share Price live?
Ans. Investors can track Natco Pharma Share Price on Univest for live updates, 52-week levels, market cap, valuation ratios and peer context. It brings Natco Pharma Stock News and company analysis together in one view.
